TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
PODD

Insulet Corporation

Healthcare · Medical Devices

139.40$ -0.8% vs. previous close Closing price · As of: Sep 22, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios PODD
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
Valuation
97.9 73.5 54.0 37.7 40.9 46.2 48.4 94.0 88.6 81.3 48.6 28.2
7.5 8.9 7.1 8.0 8.7 9.3 8.9 9.4 8.6 7.4 5.1 3.5
19.3 20.7 16.0 14.9 15.4 16.0 14.6 15.2 15.8 13.3 11.3 7.4
8.1 9.4 7.5 8.3 8.9 9.5 9.0 9.6 8.8 7.5 5.2 3.6
53.1 49.2 37.4 40.8 42.6 46.7 47.5 55.5 49.0 40.6 26.4 17.2
216.3 74.2 71.4 69.7 66.4 69.7 57.2 51.8 53.2 35.7 35.4
-0.1% 0.5% 1.3% 1.4% 1.4% 1.5% 1.4% 1.7% 1.9% 1.9% 2.8% 2.8%
Margins
65.3% 68.3% 68.9% 69.0% 69.4% 69.8% 70.4% 70.7% 71.5% 71.6% 71.0% 71.1%
8.8% 13.0% 14.0% 14.6% 15.4% 14.9% 15.5% 17.3% 17.3% 17.5% 17.5% 16.9%
7.7% 12.2% 13.1% 21.1% 21.2% 20.2% 18.3% 10.0% 9.8% 9.1% 10.4% 12.3%
-1.0% 4.1% 9.6% 11.1% 12.4% 14.1% 12.7% 16.5% 16.7% 13.9% 14.2% 9.8%
Returns
19.8% 28.2% 29.6% 39.6% 37.6% 34.5% 30.2% 16.1% 17.8% 16.3% 23.2% 26.4%
4.9% 8.0% 8.9% 13.7% 13.9% 13.5% 11.4% 6.8% 8.1% 7.7% 10.1% 11.9%
Balance Sheet & Debt
840 769 705 682 496 429 412 425 274 237 468 414
3.5 2.4 2.0 1.8 1.2 1.0 1.0 1.0 0.6 0.5 0.8 0.6
24.6% 28.3% 30.1% 34.6% 37.0% 39.2% 37.8% 42.2% 45.7% 47.5% 43.6% 44.9%
2.3 1.9 1.8 1.4 1.3 1.1 1.3 1.0 0.7 0.6 0.7 0.7
Per Share
1.63 2.95 3.17 5.36 5.69 5.65 5.43 3.34 3.48 3.50 4.31 5.41
21.15 24.29 24.15 25.37 26.83 27.96 29.67 33.40 35.69 38.32 41.32 44.00
8.25 10.49 10.72 13.53 15.12 16.36 17.96 20.71 19.59 21.44 18.56 20.49
-0.20 1.00 2.31 2.83 3.34 3.93 3.77 5.50 5.96 5.34 5.87 4.30

Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?